Dr. Stuart J. Shafer, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Miami, Lm Miller School of Medicine (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,524
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: University of Miami, Lm Miller School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
FL license ME0072261
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cleveland Clinic Martin North Hospital Stuart, FL
- Cleveland Clinic Indian River Hospital Vero Beach, FL
- Orlando Health Sebastian River Hospital Sebastian, FL
Medical groups
- Vero Beach Neurology and Research Institute LLC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,524
- Services billed
- 140,528
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 13,020 | 25 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,049 | 770 |
| Established patient office or other outpatient visit, 20-29 minutes | 423 | 378 |
| Needle measurement of electrical activity in arm or leg muscles, limited study | 389 | 203 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 380 | 26 |
| New patient office or other outpatient visit, 45-59 minutes | 296 | 296 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 270 | 264 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 259 | 21 |
| Measurement of brain wave activity (eeg), awake and asleep | 255 | 255 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 251 | 141 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 105 payments worth $3,114 in total to this clinician.
| EMD Serono, Inc. | $586 |
|---|---|
| Genentech USA, Inc. | $279 |
| Pfizer Inc. | $269 |
| Eisai Inc. | $219 |
| Lundbeck LLC | $171 |
| AbbVie Inc. | $154 |
| Tg Therapeutics, Inc. | $146 |
| Novartis Pharmaceuticals Corporation | $119 |
| Food and Beverage | $3,114 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $516,636 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment …
Novartis Pharmaceuticals Corporation - A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After …
Novartis Pharmaceuticals Corporation - Study of ocrelizumab in PPMS patients assessing upper limb function
Hoffmann-la Roche Limited - Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE
F. Hoffmann-la Roche AG - A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, F…
Novartis Pharmaceuticals Corporation - A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063)
Celgene Corporation - Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment
Roche Products Limited - A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
UCB SA · Completed · NCT06055985 - A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063)
E.r. Squibb & Sons, L.l.c. - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Hoffmann-la Roche Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.